Related Experiment Video

Updated: Jun 5, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.9K

Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable Target

Luca Quattrini1, Maria Sadiq2, Giovanni Petrarolo1

  • 1Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.

Biomedicines
|December 9, 2020
PubMed

Insights

Researchers identified aldehyde dehydrogenase 1A1 and 1A3 as potential therapeutic targets for prostate cancer. A novel compound, 3b, demonstrated significant antiproliferative effects on cancer cells with minimal impact on normal cells.

Area of Science:

  • Oncology
  • Medicinal Chemistry

Background:

  • Prostate cancer is a leading cause of cancer death in men, with limited curative therapies.
  • Novel molecular targets are crucial for developing innovative prostate cancer treatments.

Purpose of the Study:

  • To validate aldehyde dehydrogenase 1A1 and 1A3 isoforms as therapeutic targets in prostate cancer.
  • To identify potent inhibitors of these targets for potential drug development.

Main Methods:

  • Expression analysis of aldehyde dehydrogenase 1A1 and 1A3 in various prostate cell lines and primary tumors.
  • Screening of aldehyde dehydrogenase inhibitors against prostate cancer cells.
  • Evaluation of antiproliferative and colony-forming inhibition by compound 3b.

Main Results:

  • Aldehyde dehydrogenase 1A1 and 1A3 expression was confirmed in normal, benign, and malignant prostate tissues.
  • Compound 3b showed nanomolar antiproliferative activity against localized and metastatic prostate cancer cell lines (P4E6, PC3).
  • Compound 3b effectively inhibited PC3 colony formation and exhibited reduced toxicity to normal prostate cells.

Conclusions:

  • Aldehyde dehydrogenase 1A1 and 1A3 represent promising molecular targets for prostate cancer therapy.
  • Compound 3b is a potential lead compound for prostate cancer treatment due to its efficacy and selectivity.
Keywords:
ALDH inhibitorsALDH1A1ALDH1A3aldehyde dehydrogenaseimidazo[1,2-a]pyridinesprostate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K
Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity09:59

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Published on: March 31, 2023

1.3K

Related Concept Videos

Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...